New drugs: lubiprostone, ranolazine, and anidulafungin.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
D000083:Acetanilides; D000527:Alprostadil / Q000031:analogs & derivatives / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy; D000077612:Anidulafungin; D000935:Antifungal Agents / Q000627:therapeutic use; D002120:Calcium Channel Agonists / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy; D003248:Constipation / Q000188:drug therapy; D017277:Drug Approval; D054714:Echinocandins; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005227:Fatty Acids / Q000627:therapeutic use; D006801:Humans; D000068238:Lubiprostone; D010456:Peptides, Cyclic / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D000069458:Ranolazine; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D000083:Acetanilides; D000935:Antifungal Agents; D002120:Calcium Channel Agonists; D054714:Echinocandins; D004791:Enzyme Inhibitors; D005227:Fatty Acids; D010456:Peptides, Cyclic; D010879:Piperazines; D000068238:Lubiprostone; D000077612:Anidulafungin; D000069458:Ranolazine; D000527:Alprostadil